Financial Performance - The total revenue for 2022 was RMB 7,502,987,102.09, representing a 14.37% increase from RMB 6,560,077,586.40 in 2021[4]. - The net profit attributable to shareholders of the listed company was RMB 411,193,683.53, an increase of 17.97% compared to RMB 348,548,495.99 in the previous year[4]. - The operating cash flow net amount reached RMB 758,240,601.50, showing a significant increase of 192.62% from RMB 259,116,960.17 in 2021[4]. - The basic earnings per share increased to RMB 0.62, a rise of 10.71% from RMB 0.56 in the previous year[4]. - The diluted earnings per share also increased to RMB 0.61, reflecting an 8.93% growth compared to RMB 0.56 in 2021[4]. - The total comprehensive income for the year was RMB 413,373,076.38, up from RMB 313,908,790.25 in 2021, showing a growth of 31.69%[49]. - The operating profit for the year ended December 31, 2022, was RMB 476,706,533.91, compared to RMB 425,590,536.88 in 2021, indicating an increase of about 12.0%[54]. Assets and Liabilities - Total assets as of December 31, 2022, were RMB 8,265,131,332.13, up 12.73% from RMB 7,332,033,657.98 at the end of 2021[5]. - The total liabilities increased by 6.37% to RMB 3,915,226,169.32 from RMB 3,680,888,823.85 in the previous year[5]. - The net assets attributable to shareholders of the listed company rose by 18.99% to RMB 4,126,460,390.95 from RMB 3,467,941,567.45 in 2021[5]. - Current liabilities totaled RMB 3,158,485,539.10 as of December 31, 2022, compared to RMB 2,501,880,371.20 in 2021, indicating a significant increase of 26.29%[47]. - Long-term borrowings increased to RMB 545,655,801.48 in 2022 from RMB 346,196,870.64 in 2021, representing a growth of 57.67%[47]. Shareholder Information - As of December 31, 2022, the total number of shareholders was 107,300, including 38 H-share shareholders and 107,262 A-share shareholders[8]. - The proposed final dividend for the year 2022 is RMB 0.20 per share (before tax), subject to shareholder approval[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.59% of the shares, totaling 204,864,092 shares[10]. - The company emphasizes the importance of shareholder approval for the proposed dividend distribution[12]. - The proposed dividend for 2022 represents a 33.33% increase compared to the previous year's dividend[81]. Cash Flow and Investments - Cash and cash equivalents increased by 55.61% to RMB 1,158,741,565.90 compared to RMB 744,662,302.34 last year, primarily due to net proceeds from a non-public offering of A-shares amounting to RMB 244 million and an increase in customer prepayments[18][20]. - Net cash flow from operating activities reached RMB 758,240,601.50, a substantial increase of 192.62% compared to RMB 259,116,960.17 last year[23][24]. - The company achieved a fixed asset investment of RMB 720 million for the year, representing a year-on-year increase of 21%[30]. Research and Development - Research and development expenses increased by 1.26% to RMB 345,658,511.77 from RMB 341,367,394.20, reflecting ongoing investment in innovation[21]. - The company obtained 7 new product approvals for formulations and 4 for raw materials in 2022, including significant breakthroughs in drug innovation[29]. - The company plans to accelerate the development of new products, focusing on fish oil, hormones, and other specialty raw materials[33]. Market Performance - The sales revenue of the top 10 strategic formulations increased by 30% year-on-year, with the sales of fish oil soft capsules exceeding RMB 10 million[29]. - The international formulations and contract manufacturing sales saw an impressive year-on-year growth of 88%[29]. - The revenue from external transactions for the chemical raw materials segment was RMB 3,171,564,382.95 for the year ended December 31, 2022, compared to RMB 2,740,737,136.77 in 2021, marking an increase of approximately 15.7%[53]. Operational Efficiency - The company achieved a receivables turnover rate of 1,056.89% and an inventory turnover rate of 488.11% as of December 31, 2022[26]. - The company aims to enhance production efficiency and cost control through lean production and procurement management strategies[37]. - The company completed 30 technical quality projects and 21 energy transformation projects, saving RMB 20.9 million in raw material and energy consumption[30]. Compliance and Governance - The audit for the financial statements was conducted by Shinewing Certified Public Accountants, ensuring compliance with Chinese accounting standards[39]. - The company has established an audit committee to oversee financial reporting and internal controls, meeting four times during the year[44].

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a growth of 15% compared to the previous year[15]. - The net profit for the year was RMB 300 million, reflecting a 10% increase year-over-year[15]. - Operating income for 2021 reached RMB 6,560,077,586.40, representing a 9.23% increase compared to 2020[19]. - Net profits attributable to shareholders of the listed company increased by 7.29% to RMB 348,548,495.99 in 2021[19]. - The net profit attributable to the company for 2021 was RMB 57,212,663.89, an increase from RMB 34,069,550.32 in 2020, representing a growth of about 68%[27]. - The company has set a performance guidance for the next year, aiming for a revenue target of RMB 1.8 billion, which would represent a 20% increase[15]. - The gross profit margin improved to 40%, up from 35% in the previous year, indicating better cost management and pricing strategies[79]. Customer Growth - User data showed an increase in active customers, reaching 2 million, which is a 20% growth from the previous year[15]. - User data indicates a growing customer base, with an increase of 25% in active users compared to the previous year, reaching 500,000 active users[79]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[15]. - The company plans to expand its market presence in Southeast Asia, with an investment of 50 million RMB allocated for marketing and distribution channels[79]. Product Development - New product development includes the launch of three innovative pharmaceutical products, expected to contribute an additional RMB 200 million in revenue[15]. - New product development is underway, with three new pharmaceutical products expected to launch in Q3 2022, targeting a market share increase of 10%[79]. Strategic Initiatives - A strategic acquisition of a smaller pharmaceutical firm was completed, enhancing the company's product portfolio and expected to generate an additional RMB 150 million in annual revenue[15]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's production capacity by 30%[79]. Research and Development - The company has allocated RMB 100 million for research and development in new technologies for the upcoming fiscal year[15]. - The company is investing in advanced technology for drug development, with a budget of 100 million RMB dedicated to R&D over the next two years[79]. Sustainability and Corporate Responsibility - The board emphasized the importance of sustainability and corporate social responsibility initiatives, with a budget of RMB 50 million allocated for environmental projects[15]. - The company has initiated a new sustainability strategy aimed at reducing carbon emissions by 25% by 2025[79]. Financial Position - The company reported a strong cash flow position with RMB 500 million in cash reserves, providing a solid foundation for future investments[15]. - Total assets as of December 31, 2021, were RMB 7,332,033,657.98, reflecting a 3.37% increase from the previous year[19]. - Total liabilities decreased by 0.56% to RMB 3,680,888,823.85 as of December 31, 2021[19]. Shareholder Information - The total number of shares as of December 31, 2021, was 627,367,447, an increase from 621,859,447 shares in 2020[36]. - The company plans to propose a final dividend of RMB 0.15 per share based on a total share count of 669,627,235, subject to shareholder approval[62]. - The proposed A share issuance is currently in progress, and the Company will not discuss the profit distribution plan for 2021 until after the issuance is completed[61]. Management and Governance - The term of the current Directors, Supervisors, and Senior Officers will end on December 22, 2023[101]. - The company operates independently from its controlling shareholder in terms of business, assets, management, and finance[156]. - The Company has established clear responsibilities among its governance structures, including the board of directors and supervisory committee[162]. Internal Controls and Auditing - The Audit Committee confirmed that the financial statements for 2021 were prepared in accordance with the Company's accounting policies and were accurate without any material misrepresentations[143]. - An independent audit on the effectiveness of the Company's internal control was conducted by ShineWing, ensuring transparency and accountability[174]. - The internal control audit report confirmed that the Company maintained effective internal control over financial reporting as of December 31, 2021, in compliance with relevant regulations[183][186].